Moderna shares fall after Rothschild & Co Redburn downgrade to Sell
Moderna shares fell 2.9% in the afternoon session after Rothschild & Co Redburn analyst Simon Baker downgraded the company to Sell from Neutral on valuation concerns.
Shares of biotechnology company Moderna NASDAQ:MRNA fell 2.9% in the afternoon session after Rothschild & Co Redburn analyst Simon Baker downgraded the stock to Sell from Neutral on valuation concerns. Baker also lifted Moderna's price target to $81 from $40, a level that implies 46% downside.